Phase 3 Brain Cancer Trial, Recruiting NCT07461948 Sponsor: Jonsson Comprehensive Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 3 Brain Cancer Trial, Recruiting

NCT07461948
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who have a confirmed or suspected diagnosis of glioblastoma (a type of brain tumour)
  • People who are already scheduled to have standard surgery to remove a brain tumour or take a small tissue sample (biopsy)
  • People whose most recent brain scan (MRI) shows a measurable area of the tumour greater than 1ml that lights up with contrast dye

Who may not be able to join:

  • People who have a condition or abnormality that the trial investigator believes could affect their safety or the reliability of the trial data
  • People who are unable to tolerate an MRI scan, or who have a medical reason they cannot have a specific type of MRI that uses a 3-Tesla (3T) machine
  • People who have any medical reason that would make it unsafe to receive an iron-oxide nanoparticle-based contrast agent (a special dye used during imaging) — medical records will be reviewed by a qualified doctor to assess this (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Jonsson Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
27 October 2025
Est. completion
27 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean diffusion-relaxation correlation spectrum imaging (DR-CSI) value; Ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI) measures; Chemical exchange saturation transfer (CEST) values

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov